Translational Research in Endoscopy: The New Paradigm

Dong Wan Seo

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine

Researches

basic research

ex-vivo animal experiment

in-vivo animal experiment

human trial

Carcinogenesis Study after Oxysterol Treatment

University of Washington Seattle Experience



6 hr

24 hr

48 hr

Diff-Quick Staining after Oxysterol Tx



DAPI nucleus staining







Cell culture & molecular biology

interesting

time consuming

needs continuous fund

clinical applicability ?

Animal Experiment of HIFU : Limitations & Potential Complications

Dong Wan Seo

Division of Gastroenterology, Asan Medical Center University of Ulsan College of Medicine

High Intensity Focused Ultrasound (HIFU)

- ultrasound energy: extra-corporeal application
- totally non-invasive
- therapeutic potentials





MORE MENUS





Pretx imaging Tx dose: 750~1250J Automatic & manual



Pig model for HIFU

Iarge abdominal organs

- similar anatomy to human
- difficult to manipulate
- expensive

50/F Pancreatic SPN (Bx proven)



Unmet needs

- find out during clinical practice
- discussion with experts
- review of literature
- discussion with engineers & mechanics

Modification of RF electrodes

- Multiprong arrays
- Bipolar arrays
- Internally cooling electrodes
- Cluster RF
- Pulsed RF

(Goldberg SN et al *Gastrointest Endosc* 1999) (Rhim H, Dodd GD *J Clin Ultrasound* 1999)





Radiofrequency ablation: From ex vivo to in vivo animal

Dong Wan Seo

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine

EUSRA (Starmed Co, Seoul, Korea)



EUS-RFA needle Ex vivo study

Ex vivo

Target : Liver muscle

Needle : 17,18 G

Work time : 6min

RF power : 80W, 50W

1) 17G, 6min, 80W 2) 18G, 6min, 50W









Post Tx image



18G needle image





Post Tx ablation size



Post Tx image



Ex vivo test

- Bovine liver
- A 18 Gauge 1cm exposed electrode
- Power : 50 watts
- Water flow : 30ml/min



Group	Time
А	2 Min
В	4 Min
С	6 Min
D	8 Min
E	10 Min
F	12 Min

EUSRA RFA ex vivo data





50 60 70 80 90 100 110 120 130 140 150

Group B: 50watt, 6min

40 50 60 70 80

Group C: 80watt, 6min





Group E : 50watt, 12min





Group F: 80watt, 12min

EUSRA RFA ex vivo data

summation of ablation zone for large tumor ablation



EUS-RFA needle In vivo animal study

EUS-guided RFA image





Animal study



- 18G needle, 6min, 50W
- 18G needle, 12min, 80W (Max)

Pancreas

18G needle, 6min, 50W

Ultrasound image Liver, 18G, 6min, 50W



Ultrasound image Pancrease, 18G, 6min, 50W



Post Tx ablation image & size 18G, 6min, 50W





Post Tx ablation image 18G, 6min, 50W


Post Tx ablation size 18G, 6min, 50W



Scope이 지나간 stomach wall image





EUS-guided radiofrequency ablation of porcine pancreas

<u>Hong Jun Kim</u>, Dong Wan Seo, Su Hui Kim¹, Choong Heon Ryu, Sang Soo Lee, Sung-Koo Lee, Myung-Hwan Kim

Department of Internal Medicine, Asan Medical Center, ¹Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, Korea

Factors affecting efficacy of EUS-RFA

Length of delivery system

Thickness of electrode

Length of exposed electrode

Needle electrode assembly

18-gauge RFA electrode (STARmed, Korea) Total length : 150 cm Exposed electrode + delivery system Exposed electrode length : 1cm Echogenic Needle-shaped Cooling system : 30ml/min

VIVA RF system (STARmed, Korea)





EUS-guided RFA in animal model



On day 7 after EUS-RFA

1. Laparotomy



Body weight and performance
Laboratory tests

RESULTS

Baseline characteristics

	Mean±S.D
Body weight (kg)	34.6±1.6
Serum AST (U/L)	86.3±50.0
Serum ALT (U/L)	23.3±4.9
Serum amylase (U/L)	3005.0±367.7
Serum lipase (U/L)	15.5±2.1

Size of ablated lesions

	Mean±S.D
Diameter of RFA lesion(mm) - EUS	14.5±1.5
Diameter of RFA lesion(mm) - laparotomy	23.0±6.9

Gross pathology

Ablated lesion was demarcated from normal parenchyme by fibrous wall.



Histopathological examination



Specimen from a histopathological examination(H&E, orig. mag. $\times 40$)

Normal pancreas Fibrous wall. **Fibrous wall** Necrotic zone

Specimen from a histopathological examination(H&E, orig. mag. $\times 200$)

Complications

- No signs of distress
- No significant changes of body weight

Fibrosis or adhesion in 3 pigs

Adhesion to the stomach wall

Adhesion to the bowel



SUMMARY

- Technically feasible to perform EUS-guided RFA of porcine pancreas
- Successful formation of ablated lesion about 23 mm in diameter
- No significant complication
- Fibrosis and adhesion in 3 pigs
- No signs of distress and no abnormal laboratory findings in all pigs

CONCLUSION

 EUS-guided RFA of porcine pancreas was feasible and effective.

 We could make ablated lesion about 23 mm in diameter without significant complication.

 Application of EUS-RFA to the human pancreatic lesion can be possible.

EUS-guided RFA

NEW METHODS: Experimental Endoscopy

EUS-guided radiofrequency ablation of the porcine pancreas

Hong Jun Kim, MD,¹ Dong-Wan Seo, MD, PhD,¹ Aizan Hassanuddin, MMed, MRCP,¹ Su-Hui Kim,² Hee Jung Chae,³ Ji Woong Jang, MD,¹ Do Hyun Park, MD, PhD,¹ Sang Soo Lee, MD, PhD,¹ Sung-Koo Lee, MD, PhD,¹ Myung-Hwan Kim, MD, PhD¹

Seoul, Korea

(Gastrointest Endosc 2012;76:1039-43)

Complications



Perinephric fibrosis

Perigastric adhesion

(Gastrointest Endosc 2012;76:1039-43)

EUS-guided RFA: ascites model



EUS-RFA human application

Pancreatic cancer

EUS-RFA of PCa: Human trial

IRB approved inclusion criteria

histologically confirmed PCa

advanced & unresectable case

failure to chemotherapy: PD

M/66 Pancreas head cancer Metal stent guided SBRT (26Gy/4 Fr) GT chemotherapy #4

Op tried but failed d/t omental seeding -> 2nd line CTx #3 (Folfox)-> disease progression



EUS-RFA of Pca: Human case 3



EUS-RFA of PCa: Human case 3



1 day after EUS-RFA

EUS-RFA of PCa: Human case 3



1 day after EUS-RFA 2 month after EUS-RFA

EUS-RFA for pancreatic cancer

NEW METHODS

Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer

Tae Jun Song, MD, PhD,¹ Dong Wan Seo, MD, PhD,¹ Sundeep Lakhtakia, MD, PhD,² Nageshwar Reddy, MD, PhD,² Dong Wook Oh, MD,¹ Do Hyun Park, MD, PhD,¹ Sang Soo Lee, MD, PhD,¹ Sung Koo Lee, MD, PhD,¹ Myung-Hwan Kim, MD, PhD¹

Seoul, South Korea

Conclusions: EUS-RFA could be a technically feasible and safe option for patients with unresectable pancreatic cancer.

(Song TJ et al. Gastrointest Endosc 2016;83:440-3)

Thickness of needle design





EUS-RFA for Benign

Pancreatic Tumor

Case

F/69, Pancreatic neuroendcrime tumor

A CT scan demonstrated a well-enhanced pancreatic body tumor

Baseline characteristics and outcomes (n=10)

No	Age	Se	Symptom	Dx	site	Size	Post-ablati	Response	Sess	Adverse event
-		x				(mm)	on size		ions	
1	34	Μ	Hypoglyce mia	Insulin oma	Head	12	0	Complete	1	-
2	21	F	Incidental	SPN	Head	23	19	Incomplete	1	-
3	53	F	Incidental	SPN	Tail	20	0	Complete	1	-
4	53	F	Incidental	NET	Body	8	0	Complete	1	-
5	43	Μ	Incidental	NET	Body	28	7	Incomplete	2	-
6	69	F	Incidental	NET	Body	19	9	Complete	2	-
7	70	Μ	Incidental	NET	Body	20	16	Incomplete	1	-
8	40	М	Incidental	NET	Body	16	0	Complete	1	-
9	69	F	Incidental	NET	Head	28	5	Complete	3	Abdominal pain
10	62	F	Incidental	NET	Head	23	10	Complete	3	Pancreatitis

Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors

(J-H Choi et al. Endoscopy 2018)

Conclusions EUS-RFA may be a safe and potentially effective treatment option in selected patients with benign solid pancreatic tumors. Multiple sessions may be required if there is a remnant tumor, and adverse events must be carefully monitored.

Potential complications of EUS-guided RFA

- Pancreatitis
- MPD stricture
- Perforation
- Bleeding
- RFA: Pancreas is close to many vital organs

Translational Research in Endoscopy

- Iarge animal model: pig or dog
- dedicated endoscopy for animal
- research assistant team
- continuous funds application

Translational Research in Endoscopy

Our passion is most Important !!!

continuous funds application

Thank you very much